Related Experiment Video
Updated: Feb 3, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in
Mehmet G Badur1, Thangaselvam Muthusamy1, Seth J Parker1
1Department of Bioengineering, University of California, San Diego, La Jolla, CA 92037, USA.
Abstract:
Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) contribute to tumorigenesis in several cancers. Although significant research has focused on the hypermethylation phenotypes associated with (D)2-hydroxyglutarate (D2HG) accumulation, the metabolic consequences of these mutations may also provide therapeutic opportunities. Here we apply flux-based approaches to genetically engineered cell lines with an endogenous IDH1 mutation to examine the metabolic impacts of increased D2HG production and altered IDH flux as a function of IDH1 mutation or expression. D2HG synthesis in IDH1-mutant cells consumes NADPH at rates similar to de novo lipogenesis. IDH1-mutant cells exhibit increased dependence on exogenous lipid sources for in vitro growth, as removal of medium lipids slows growth more dramatically in IDH1-mutant cells compared with those expressing wild-type or enzymatically inactive alleles. NADPH regeneration may be limiting for lipogenesis and potentially redox homeostasis in IDH1-mutant cells, highlighting critical links between cellular biosynthesis and redox metabolism.
Insights
Neomorphic mutations in isocitrate dehydrogenases (IDH1/2) drive cancer. IDH1-mutant cells show increased reliance on lipids due to altered metabolism and NADPH consumption, offering potential therapeutic targets.
Area of Science:
- Biochemistry
- Cancer Metabolism
- Molecular Biology
Background:
- Neomorphic mutations in isocitrate dehydrogenases (IDH1 and IDH2) are implicated in various cancers.
- Research has focused on hypermethylation and (D)2-hydroxyglutarate (D2HG) accumulation, but metabolic consequences offer therapeutic avenues.
Purpose of the Study:
- To investigate the metabolic impacts of IDH1 mutations and D2HG production using flux-based approaches.
- To examine how IDH1 mutation or expression affects cellular metabolism and growth.
Main Methods:
- Utilized genetically engineered cell lines with endogenous IDH1 mutations.
- Applied flux-based approaches to analyze metabolic alterations.
- Assessed cell growth dependence on exogenous lipids under varying conditions.
Main Results:
- D2HG synthesis in IDH1-mutant cells consumes NADPH at rates comparable to de novo lipogenesis.
- IDH1-mutant cells display heightened dependence on exogenous lipids for in vitro growth.
- NADPH regeneration appears limited in IDH1-mutant cells, impacting lipogenesis and redox homeostasis.
Conclusions:
- IDH1 mutations create critical links between cellular biosynthesis and redox metabolism.
- Altered metabolic pathways and NADPH consumption in IDH1-mutant cells present potential therapeutic vulnerabilities.
- Targeting lipid metabolism or NADPH regeneration could be a strategy against IDH1-mutant cancers.
Related Concept Videos
Limiting Reactant
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Viral Mutations
The Number e as a Limit

